Assignment history

Inventors

• Ge Wei (Employer: Halozyme Inc. at time of filing)
• H. Michael Shepard (Employer: Halozyme Inc. at time of filing)
• Qiping Zhao (Employer: Halozyme Inc. at time of filing)
• Robert James Connor (Employer: Halozyme Inc. at time of filing)

All named inventors were associated with Halozyme Inc. at the time of filing, which is the original assignee. There are no immediate indications that inventors departed the original assignee shortly after filing.

Original assignee

The entity named on the issued patent is Halozyme Inc. Their primary line of business is biopharmaceutical technology, focusing on oncology and rare diseases, particularly through their proprietary ENHANZE® drug delivery technology that utilizes recombinant human hyaluronidase (rHuPH20). This technology directly relates to the claims of US12195773, which describes PH20 polypeptide variants, formulations, and uses thereof. Halozyme Therapeutics, Inc. (which appears to be the public entity name for Halozyme Inc.) ships products embodying the claims, such as Hylenex recombinant, an FDA-approved hyaluronidase injection, and also licenses its ENHANZE® technology to other major pharmaceutical companies for use in their products. Halozyme Therapeutics, Inc. is currently an operating, publicly traded company on NASDAQ (HALO) with a market capitalization of $8.30B as of May 13, 2026.

Assignment timeline

A search of the USPTO Assignment Center for US Patent 12195773 (https://assignmentcenter.uspto.gov/) as of 2026-05-16 yielded no recorded assignments. This indicates that the ownership of the patent has not been formally transferred or recorded with the USPTO since its issuance.

Timeline diagram

timeline
    title Ownership of US 12195773
    2011 : Priority date
    2024 : Application filed by Halozyme Inc
    2025 : Patent issued to Halozyme Inc

NPE / troll-pattern signals

1. Shell-entity transfer — Not present. There are no recorded assignments, so no transfer to a shell entity has been documented.
2. Known asserter in the chain — Not present. There are no recorded assignments to any entity, let alone a known asserter. Halozyme Inc. is a known operating company.
3. Repeat correspondent across the chain — Not present. With no recorded assignments, there is no correspondent chain to analyze.
4. Cascading transfers — Not present. No assignments are recorded.
5. Pre-litigation transfer — Not present. No assignments are recorded.
6. Bankruptcy fire-sale — Not present. Halozyme Therapeutics, Inc. is an active, publicly traded company and has not filed for bankruptcy.
7. Privateering — Not present. No assignments indicate such a transfer. Halozyme develops and licenses its technology, which is a business model, not privateering in the context of patent assertion.
8. Defensive aggregator (anti-NPE) — Not present. The patent remains with the original operating company, Halozyme Inc.

Verdict

Operating-company assertion

This verdict is based on the fact that US Patent 12195773 is currently held by its original assignee, Halozyme Inc., a legitimate operating biopharmaceutical company. Halozyme actively uses and licenses the technology covered by this patent in its commercial products and drug delivery platforms. There are no recorded assignments of the issued patent in the USPTO Assignment Center, indicating continued ownership by the operating entity.

Verification: USPTO Assignment Center search for US12195773